【招银国际】We expect 1H24 to be still profitable.pdf

Overseas CXO/ life science upstream 2Q24 review: life science upstream continuing to expect demand recovery

1H24 VNB beat with margin recovery; expect total >US$7bn cash returns to shareholders in FY24

SJM Holdings Expect catalyst

Expecting bottoming out

Earnings expectation is settling

Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL

Expecting a solid 1H23

China's Economy：Money and Credit Growth Beats Expectations; the Central Bank might Slightly Rein in Its Pace of Monetary Loosening

Optimized CoR guidance beat expectations

Core business recovery on track with more to expect on new initiatives